Ryvu Therapeutics (RVU) Q2 2025 earnings summary

Executive summary

• Operating revenue for H1 2025 was PLN 42.4M, down from PLN 48.5M year-over-year, mainly due to lower R&D project revenues and the absence of a milestone payment received in H1 2024.

• Net loss increased to PLN 58.9M from PLN 49.8M year-over-year, driven by lower revenues and a negative impact from NodThera share valuation, partially offset by a positive put option effect.

• Strategic reorganization, including a 30% workforce reduction and pipeline adjustments, was implemented to extend the cash runway to H2 2026 and focus on RVU120 and early pipeline development.

Financial highlights

• Total assets as of June 30, 2025, were PLN 281.2M, down from PLN 378.8M at year-end 2024, mainly due to R&D expenditures.

• Cash and cash equivalents stood at PLN 107.2M, with additional financial assets of PLN 48.9M.

• Total liabilities increased to PLN 185.9M, with long-term liabilities at PLN 116.2M, mainly from EIB loans.

• Net cash outflow from operating activities was PLN 68.6M; investing activities generated PLN 18.2M, and financing activities used PLN 2.2M.

• Book value per share was PLN 4.12, down from PLN 8.88 at year-end 2024.

Outlook and guidance

• Cash position and EIB financing support ongoing operations and planned investments, with a cash runway extended to H2 2026.

• Future revenues depend on successful commercialization of R&D projects and achieving milestones in collaborations.

• Key objectives include advancing RVU120 clinical development, supporting partnered candidate SEL24, and progressing preclinical programs.